TP53 and lung cancer: To validate the NMD-inhibiting capacity of molecules 1a and 2a, Calu-6 lung cancer cells carrying an NMD-activating nonsense mutation in the TP53 gene (leading to NMD of the corresponding mRNA) were incubated with each molecule at concentrations near its working concentration.